Approval received for innovative vial adaptor, available now for market introduction

Bubendorf, Switzerland, Friday, August 30, 2018 – CIS Pharma announces the approval of a vial adaptor specific for the preparation and injection of intracameral cefuroxime. Consequently, the adaptor was produced [...]

Intracameral cefuroxime launched in Europe

Bubendorf, Switzerland, Monday, February 26, 2018  - CIS Pharma’s licensee has launched intracameral cefuroxime across Europe. Among others, cataract clinics in France, Germany, Spain, Italy and Netherlands will be supplied [...]

Approval received for intracameral cefuroxime for antibiotic prophylaxis of endophthalmitis after cataract surgery

Uppsala, Sweden, Mai 24, 2016 – The marketing authorization application for intracameral cefuroxime has been finalized with a positive outcome. The decentralized procedure was led by Sweden as reference member [...]

Development of vial adaptor for preparation of intracameral cefuroxime

Bubendorf, April 10, 2016 – CIS Pharma enters agreement with West Pharma to develop a vial adaptor specific for the preparation and injection of intracameral cefuroxime. The development is innovative [...]

Submission of marketing authorization application for intracameral cefuroxime completed

Uppsala, Sweden, July 20, 2015 – CIS Pharma has submitted to the Swedish competent authority MPA the marketing authorization application for intracameral cefuroxime. The decentralized procedure is led by Sweden [...]

CIS Pharma signs development and licensing agreement with marketing partner for cefuroxime

Bubendorf, Switzerland, October 12, 2014 – CIS Pharma signs development and licensing agreement with licensee. Having developed intracameral cefuroxime as a response to the clinical demand for such a product, [...]